Pramlintide/insulin A21G (development name ADO09) is a combination of the amylin analogue pramlintide and an insulin analog. It is being developed by Adocia for diabetes.[1][2][3]
| Combination of | |
|---|---|
| Pramlintide | Amylin analog |
| Insulin A21G | Insulin analog |
| Clinical data | |
| Other names | ADO09 |
| Legal status | |
| Legal status |
|
References
edit- ^ Andersen, Grit; Meiffren, Grégory; Famulla, Susanne; Heise, Tim; Ranson, Aymeric; Seroussi, Cyril; Eloy, Rosy; Gaudier, Martin; Charvet, Richard; Chan, You-Ping; Soula, Olivier; DeVries, J. Hans (April 2021). "ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes". Diabetes, Obesity and Metabolism. 23 (4): 961–970. doi:10.1111/dom.14302. PMID 33336850. S2CID 229317541.
- ^ Meiffren, GréGory; Andersen, Grit; Eloy, Rosy; Seroussi, Cyril; MéGret, Claire; Famulla, Susanne; Chan, You-Ping; Gaudier, Martin; Soula, Olivier; Devries, J. Hans; Heise, Tim (1 June 2020). "112-LB: ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)". Diabetes. 69 (Supplement_1). doi:10.2337/db20-112-LB. S2CID 225836057.
- ^ Andersen, Grit; Eloy, Rosy; Famulla, Susanne; Heise, Tim; Meiffren, Grégory; Seroussi, Cyril; Gaudier, Martin; Mégret, Claire; Chan, You-Ping; Soula, Olivier; Riddle, Matthew (May 2023). "A co-formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes". Diabetes, Obesity and Metabolism. 25 (5): 1241–1248. doi:10.1111/dom.14972. PMID 36633505. S2CID 255747311.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |